Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® IV)

M. Morfini, G. Longo, A. Messori, M. Lee, G. White, P. Mannucci, H. R. Roberts, C. W. McMillan, J. E. Addiego, H. H. Brackmann, D. Brettler, B. Ewenstein, J. Cox Gill, J. Goldsmith, F. Gringeri, M. Hilgartner, K. Hoots, J. Ingersley, C. Kessler

Research output: Contribution to journalArticle

Abstract

A recombinant FVIII preparation, Recombinate®, was compared with a high-purity plasma-derived concentrate, Hemofil® M, in 47 hemophilia A patients in a cross-over evaluation of pharmacokinetic properties. The recombinant material showed a significantly lower clearance, volume of distribution, and higher in vivo recovery, but a similar half-life to the plasma-based product. In a comparison with reported data from other standard concentrates, the recombinant preparation exhibited potentially better pharmacokinetic properties in that its clearance was slower and its half-life was longer. We conclude that the recombinant DNA method of preparation does not adversely affect the biological and pharmacological characteristics of the factor VIII molecule.

Original languageEnglish
Pages (from-to)433-435
Number of pages3
JournalThrombosis and Haemostasis
Volume68
Issue number4
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® IV)'. Together they form a unique fingerprint.

  • Cite this

    Morfini, M., Longo, G., Messori, A., Lee, M., White, G., Mannucci, P., Roberts, H. R., McMillan, C. W., Addiego, J. E., Brackmann, H. H., Brettler, D., Ewenstein, B., Cox Gill, J., Goldsmith, J., Gringeri, F., Hilgartner, M., Hoots, K., Ingersley, J., & Kessler, C. (1992). Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil® IV). Thrombosis and Haemostasis, 68(4), 433-435.